Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Passage Bio logo — Our mission is to improve the lives of patients with neurode...

Passage Bio

Our mission is to improve the lives of patients with neurodegenerative diseases

Founded 2017 United States Philadelphia, United States 43 employees Post-IPO Equity Total: $379.50M Biotechnology, Health Care +1

General Information

Company Name Passage Bio
Founded Year 2017
Location United States Philadelphia, United States
Founders / Decision Makers
Team member Team member Team member
Employees 43
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Business Model B2B2C, B2B
Revenue Model One Time Purchase, Value Based Pricing, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Passage Bio. To contact Passage Bio, visit passagebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Passage Bio compare?

A PDF of Passage Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Passage Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Passage Bio

Passage Bio, founded in 2017 and headquartered in the United States, is a clinical stage genetic medicines company dedicated to improving the lives of patients with neurodegenerative diseases. The company operates within the Biotechnology, Health Care, and Health and Wellness industries.

Their mission, encapsulated by the slogan "Our mission is to improve the lives of patients with neurodegenerative diseases," is pursued through the development of cutting-edge, one-time therapies that target the underlying pathology of these conditions. Their lead candidate, PBFT02, aims to treat frontotemporal dementia by elevating progranulin levels, enhancing lysosomal function, and slowing disease progression.

Passage Bio secured its last significant funding — a $154.00M post-IPO equity investment — on January 21, 2021. This substantial backing underscores the investor confidence in their strategic vision and clinical advancements.

Business keywords: neurodegenerative diseases, genetic medicines, clinical stage, one-time therapies, lysosomal function restoration, progranulin elevation, AAV-delivered therapeutics, monogenic CNS diseases, gene therapy, frontotemporal dementia, research collaboration, preclinical work, clinical development, regulatory affairs, patient advocacy outreach

Services & Products

Development of genetic medicines
Clinical trials for CNS disorders
Gene therapy solutions

Target Customers

Patients with neurodegenerative diseases Healthcare professionals specializing in CNS disorders Biotech and pharmaceutical investors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $154.00M -
21 Jan 2021
Series B $110.00M 10
Lilly Asia Ventures New Leaf Venture Partners Frazier Healthcare Partners
Lilly Asia Ventures, New Leaf Venture Partners +8
04 Sep 2019
Series A $115.50M -
15 Feb 2019

Latest News

View All
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more — Fiercebiotech.com
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more
Fiercebiotech.com Jan 13, 2025

Passage Bio Alternatives & Competitors

View All Alternatives
Passage Bio vs
Lexeo Therapeutics
Lexeo Therapeutics United States

Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's d...

Post-IPO Equity
97 employees
Biotechnology, Health and Wellness
Compare Passage Bio vs Lexeo Therapeutics
Passage Bio vs
VBL Therapeutics (Nasdaq:VBLT)
VBL Therapeutics (Nasdaq:VBLT) Israel

Engineering the future of targeted medicines, breaking barriers to develop the next generation thera...

Post-IPO Equity
15 employees
Biotechnology, Health Care
Compare Passage Bio vs VBL Therapeutics (Nasdaq:VBLT)
Passage Bio vs
ProJenX
ProJenX United States

ProJenX is a clinical-stage biotech developing novel, brain-penetrant MAP4K inhibitors for ALS & oth...

Series A
9 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Passage Bio

Our mission is to improve the lives of patients with neurodegenerative diseases
Passage Bio was founded in 2017.
Passage Bio is headquartered in Philadelphia, United States.
Passage Bio operates in Biotechnology, Health Care and Health and Wellness. Its work centres on neurodegenerative diseases, genetic medicines, clinical stage and one-time therapies. Its customers include Patients with neurodegenerative diseases, Healthcare professionals specializing in CNS disorders and Biotech and pharmaceutical investors.
Passage Bio has a B2B2C and B2B business model. Its revenue comes from One Time Purchase, Value Based Pricing and Licensing.
Passage Bio has approximately 43 employees.
Passage Bio has completed 3 funding rounds, raising a total of $379.50M. The latest funding stage is Post-IPO Equity.
Passage Bio offers: Development of genetic medicines, Clinical trials for CNS disorders, Gene therapy solutions.
Top alternatives and competitors to Passage Bio include Lexeo Therapeutics, VBL Therapeutics (Nasdaq:VBLT), ProJenX, HuidaGene Therapeutics, Spinogenix, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Passage Bio and Lexeo Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Passage Bio, https://bouncewatch.com/company/passage-bio, updated 30 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes